System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Denis Angoulvant is an expert in Cardiology at Centre Hospitalier Universitaire de Tours (France). As of October 2026, ScienceLeadR ranks Denis Angoulvant in the top 1% of experts worldwide for Myocardial Ischemia and Arteriosclerosis. Denis Angoulvant has authored 381 publications, the most recent in 2026, and is an investigator in 35 clinical trials, 3 of them ongoing. SLR score: 1,436 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Denis Angoulvant Centre Hospitalier Universitaire de Tours France
1 436 ScienceLeadR Reputation 1436

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Pharmacy - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2026
Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 381

Citations

Citations: 16 529 1st author: 28 Last author: 41 Unique author: 1

Main journals

Eur Heart J 41
Arch Cardiovasc Dis 31
Archives of cardiovascular diseases. Supplements 26
Circulation 18
Archives of Cardiovascular Diseases Supplements 16

Best Journals

Eur Heart J 20
N Engl J Med 16
Circulation 7

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinical outcomes of FFR-guided revascularisation of non-culprit lesions in NSTE-ACS.
PMID 42765399 — angiography, cardiac surgical procedures, wounds and injuries		EuroIntervention20261
Influenza vaccination as a modulator of inflammaging: trained tolerance as a mechanistic lens on heterologous effects in age-related diseases.
PMID 42731600 — cells, vaccines, aging, vaccination, influenza, human, influenza vaccines, frailty, infections		Ageing Res Rev20260
LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.
PMID 42666092 — cholesterol, ldl, myocardial infarction, percutaneous coronary intervention, cholesterol, odds ratio, therapeutics		JAMA Top journal20262
Restrictive vs Liberal Transfusion Strategy After Myocardial Infarction: A Post Hoc Analysis of the MINT Randomized Clinical Trial.
PMID 42507445 — hemoglobins, myocardial infarction, anemia, heart failure, probability, heart, clinical medicine		JAMA Netw Open20260
A simplified geometric CMR method for reproducible quantification of left ventricular thrombus volume : Left Ventricular thrombus: a standardized measurement method.
PMID 42295559 — research design, bias, myocardial infarction, diagnostic techniques, cardiovascular		Int J Cardiovasc Imaging20260

Clinical Studies 35

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

N/A 17
Phase 3 12
Phase 4 5
Phase 2/Phase 3 1

By status:

Completed 21
Unknown 4
Active not recruiting 3
Recruiting 3
Terminated 3
Withdrawn 1

By type:

Interventional 26
Observational 9

By Monocentric/Multicentric:

monocentric 19
multicentric2to4 1
multicentric5to9 1
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
NCT05627375 — anticoagulants, thromboembolism, embolism, coronary artery disease, pharmaceutical preparations, cardiovascular diseases, venous thrombosis, clopidogrel, aspirin, secondary prevention, pulmonary embolism, therapeutics, venous thromboembolism, thrombosis, direct-acting oral anticoagulants		Phase 3Recruiting2023
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
NCT04951856 — injections, myocardial infarction, st elevation myocardial infarction, hydroxymethylglutaryl-coa reductase inhibitors, non-st elevated myocardial infarction, random allocation, injections, subcutaneous		Phase 4Active not recruiting2021
Pulmonary Embolism International THrOmbolysis Study 3
NCT04430569 — embolism, plasminogen, plasminogen activators, tissue plasminogen activator, pulmonary embolism, therapeutics, tissues, infusions, intravenous		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS